Amyotrophic Lateral Sclerosis (ALS)

Trial to Evaluate the Hormone Drug Acthar in ALS

A 40-person phase 2 clinical trial to test the safety and tolerability of Questcor Pharmaceuticals’ H.P. Acthar Gel (Acthar) in people with amyotrophic lateral sclerosis (ALS) has opened at a trial site in Phoenix, Ariz.

ALS — James Shorter, Ph.D.

James Shorter, associate professor of biochemistry and biophysics at the University of Pennsylvania in Philadelphia, was awarded an MDA research grant totaling $300,000 over a period of three years to develop an experimental approach targeted at protein aggregates in amyotrophic lateral sclerosis (ALS).

SBMA/ALS — Constanza Cortes, Ph.D.

Constanza Cortes, a postdoctoral researcher at the University of California, San Diego, was awarded an MDA development grant totaling $177,410 over a period of three years to study the role of a cell recycling system in spinal-bulbar muscular atrophy (SBMA or Kennedy disease) and amyotrophic lateral sclerosis (ALS).

'Sugar' Molecule Delays Disease Progression in ALS Mice

Treatment with a small molecule called trehalose was associated with slower disease progression and longer life span in mice with a disease mimicking amyotrophic lateral sclerosis (ALS), an MDA-supported research team has reported.

Trehalose is a compound composed of two glucose (sugar) molecules.

ALS — NeuRx Diaphragm Pacing System (DPS)

The Muscular Dystrophy Association has committed $750,000 to help support a phase 2 clinical trial assessing the ability of the NeuRx Diaphragm Pacing System (DPS) to improve respiratory function and quality of life in people with amyotrophic lateral sclerosis (ALS).

Multicenter Trial to Test Safety of Mexiletine in Sporadic ALS

The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) is actively seeking participants for a phase 2 clinical trial that will evaluate the safety and tolerability of mexiletine in people with the sporadic form of amyotrophic lateral sclerosis (ALS).

Approximately 90 to 95 percent of ALS is sporadic, in which there is no known family history of the disease.

Computer Error Results in Wrong Participants Getting Placebo in Tirasemtiv Trial

South San Francisco biotechnology company Cytokinetics announced July 8, 2013, that a computer program error occurred in its phase 2b BENEFIT-ALS clinical trial designed to evaluate the safety, tolerability and potential efficacy of tirasemtiv in people with amyotrophic lateral sclerosis (ALS)

A ‘Transport Problem’ May Cause Motor Neuron Death

Axonal transport is the process that is responsible for moving nutrients, proteins and other vital cellular cargo to and from the cell bodies in motor neurons – the muscle-controlling nerve cells that are lost in amyotrophic lateral sclerosis (ALS).

ALS: Misfolded TDP43 Appears to Spread

A team of researchers based at institutions in the United States and Germany has described the path amyotrophic lateral sclerosis (ALS) appears to take as it progresses through different areas of the central nervous system (the brain and spinal cord).

Generic Riluzole on the Market

The U.S. Food and Drug Administration (FDA) granted approval June 18, 2013, to Apotex Corp., Glenmark Generics and Sun Pharmaceutical Industries to market generic versions of the prescription amyotrophic lateral sclerosis (ALS) drug riluzole.

Pages